This work is licensed under the Creative Commons Attribution 4.0 International License.
Cancer [Internet]. [cited 2021 Nov 11]. Available from: https://www.who.int/news-room/fact-sheets/detail/cancerSearch in Google Scholar
Targeted therapy for cancer - NCI [Internet]. 2014 [cited 2021 Sept 15]. Available from: https://www.cancer.gov/about-cancer/treatment/types/targeted-therapiesSearch in Google Scholar
Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. Cancer genome landscapes. Science. 2013 Mar 29;339(6127):1546-58. DOI: 10.1126/science.1235122Search in Google Scholar
Fiore LD, Brophy MT, Turek S, Kudesia V, Ramnath N, Shannon C, et al. The va point-of-care precision oncology program: balancing access with rapid learning in molecular cancer medicine. Biomark Cancer. 2016;8:9-16. DOI: 10.4137/BIC.S37548Search in Google Scholar
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. DOI: 10.3322/caac.21492Search in Google Scholar
AACR Project GENIE Consortium. Aacr project genie: powering precision medicine through an international consortium. Cancer Discov. 2017 Aug;7(8):818-31.Search in Google Scholar
Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015 Feb 26;372(9):793-5. DOI: 10.1056/NEJMp1500523Search in Google Scholar
Miller FA, Krueger P, Christensen RJ, Ahern C, Carter RF, Kamel-Reid S. Postal survey of physicians and laboratories: Practices and perceptions of molecular oncology testing. BMC Health Services Research. 2009 Jul 30;9(1):131. DOI: 10.1186/1472-6963-9-131Search in Google Scholar
Schink JC, Trosman JR, Weldon CB, Siziopikou KP, Tsongalis GJ, Rademaker AW, et al. Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers. J Natl Cancer Inst. 2014 Oct;106(10):dju256. DOI: 10.1093/jnci/dju256Search in Google Scholar
Miller FA, Hayeems RZ, Bytautas JP, Bedard PL, Ernst S, Hirte H, et al. Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer care. Eur J Hum Genet. 2014 Mar;22(3):391-5. DOI: 10.1038/ejhg.2013.158Search in Google Scholar
Rheinbay E. The genomic landscape of advanced cancer. Nat Cancer. 2020 Apr;1(4):372-3. DOI: 10.1038/s43018-020-0057-zSearch in Google Scholar
Li E, Beard C, Jaenisch R. Role for DNA methylation in genomic imprinting. Nature. 1993 Nov 25;366(6453):362-5. DOI: 10.1038/366362a0Search in Google Scholar
Cui H, Cruz-Correa M, Giardiello FM, Hutcheon DF, Kafonek DR, Brandenburg S, et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science. 2003 Mar 14;299(5613):1753-5. DOI: 10.1126/science.1080902Search in Google Scholar
El-Deiry WS, Goldberg RM, Lenz HJ, Shields AF, Gibney GT, Tan AR, et al. The current state of molecular testing in the treatment of patients with solid tumors, 2019. CA Cancer J Clin. 2019 Jul;69(4):305-43. DOI: 10.3322/caac.21560Search in Google Scholar
du Rusquec P, de Calbiac O, Robert M, Campone M, Frenel JS. Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data. Cancer Manag Res. 2019 May 15;11:4297-312. DOI: 10.2147/CMAR.S151023Search in Google Scholar
Tykodi SS, Schadendorf D, Cella D, Reck M, Harrington K, Wagner S, et al. Patient-reported outcomes with nivolumab in advanced solid cancers. Cancer Treat Rev. 2018 Nov;70:75-87. DOI: 10.1016/j.ctrv.2018.08.001Search in Google Scholar
Chrzanowska NM, Kowalewski J, Lewandowska MA. Use of fluorescence in situ hybridization (Fish) in diagnosis and tailored therapies in solid tumors. Molecules. 2020 Apr 17;25(8):1864. DOI: 10.3390/molecules25081864Search in Google Scholar
Rosa FE, Santos RM, Rogatto SR, Domingues M a. C. Chromogenic in situ hybridization compared with other approaches to evaluate HER2/neu status in breast carcinomas. Braz J Med Biol Res. 2013 Mar;46(3):207-16. DOI: 10.1590/1414-431X20132483Search in Google Scholar
Sáez A, Andreu FJ, Seguí MA, Baré ML, Fernández S, Dinarés C, et al. HER-2 gene amplification by chromogenic in situ hybridisation (Cish) compared with fluorescence in situ hybridisation (Fish) in breast cancer-A study of two hundred cases. Breast. 2006 Aug;15(4):519-27. DOI: 10.1016/j.breast.2005.09.008Search in Google Scholar
Broholm H, Born PW, Guterbaum D, Dyrbye H, Laursen H. Detecting chromosomal alterations at 1p and 19q by FISH and DNA fragment analysis--a comparative study in human gliomas. Clin Neuropathol. 2008;27(6):378-87. DOI: 10.5414/NPP27378Search in Google Scholar
Home - nih genetic testing registry (GTR) - ncbi [Internet]. [cited 2023 Jun 12]. Available from: https://www.ncbi.nlm.nih.gov/gtr/Search in Google Scholar
Wideroff L, Freedman AN, Olson L, Klabunde CN, Davis W, Srinath KP, et al. Physician use of genetic testing for cancer susceptibility: results of a national survey. Cancer Epidemiol Biomarkers Prev. 2003 Apr;12(4):295-303.Search in Google Scholar
Hicks DG, Kulkarni S. HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools. Am J Clin Pathol. 2008 Feb;129(2):263-73. DOI: 10.1309/99AE032R9FM8WND1Search in Google Scholar
Combining highly multiplexed pcr with semiconductor-based sequencing for rapid cancer genotyping. The Journal of Molecular Diagnostics. 2013 Mar 1;15(2):171-6. DOI: 10.1016/j. jmoldx.2012.09.003Search in Google Scholar
Gray SW, Hicks-Courant K, Cronin A, Rollins BJ, Weeks JC. Physicians’ attitudes about multiplex tumor genomic testing. J Clin Oncol. 2014 May 1;32(13):1317-23. DOI: 10.1200/JCO.2013.52.4298Search in Google Scholar
Gray SW, Park ER, Najita J, Martins Y, Traeger L, Bair E, et al. Oncologists’ and cancer patients’ views on whole-exome sequencing and incidental findings: results from the CanSeq study. Genet Med. 2016 Oct;18(10):1011-9. DOI: 10.1038/gim.2015.207Search in Google Scholar
Johnson LM, Valdez JM, Quinn EA, Sykes AD, McGee RB, Nuccio R, et al. Integrating next-generation sequencing into pediatric oncology practice: An assessment of physician confidence and understanding of clinical genomics. Cancer. 2017 Jun 15;123(12):2352-9. DOI: 10.1002/cncr.30581Search in Google Scholar
Gene expression profiling tests for early-stage invasive breast cancer: a health technology assessment. Ont Health Technol Assess Ser. 2020 Mar 6;20(10):1-234.Search in Google Scholar
Ananda G, Mockus S, Lundquist M, Spotlow V, Simons A, Mitchell T, et al. Development and validation of the JAX Cancer Treatment ProfileTM for detection of clinically actionable mutations in solid tumors. Exp Mol Pathol. 2015 Feb;98(1):106-12. DOI: 10.1016/j. yexmp.2014.12.009Search in Google Scholar
Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008 Oct 23;359(17):1757-65. DOI: 10.1056/NEJMoa0804385Search in Google Scholar
Pulumati A, Pulumati A, Dwarakanath BS, Verma A, Papineni RVL. Technological advancements in cancer diagnostics: Improvements and limitations. Cancer Rep (Hoboken). 2023 Jan 6;6(2):e1764. DOI: 10.1002/cnr2.1764Search in Google Scholar
Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013 Nov;31(11):1023-31. DOI: 10.1038/nbt.2696Search in Google Scholar
Cottrell CE, Al-Kateb H, Bredemeyer AJ, Duncavage EJ, Spencer DH, Abel HJ, et al. Validation of a next-generation sequencing assay for clinical molecular oncology. J Mol Diagn. 2014 Jan;16(1):89-105.Search in Google Scholar
Kanagal-Shamanna R, Portier BP, Singh RR, Routbort MJ, Aldape KD, Handal BA, et al. Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics. Mod Pathol. 2014 Feb;27(2):314-27. DOI: 10.1038/modpathol.2013.122Search in Google Scholar
Tsongalis GJ, Peterson JD, de Abreu FB, Tunkey CD, Gallagher TL, Strausbaugh LD, et al. Routine use of the Ion Torrent AmpliSeqTM Cancer Hotspot Panel for identification of clinically actionable somatic mutations. Clin Chem Lab Med. 2014 May;52(5):707-14. DOI: 10.1515/cclm-2013-0883Search in Google Scholar
Gottlieb B, Beitel LK, Trifiro M. Changing genetic paradigms: creating next-generation genetic databases as tools to understand the emerging complexities of genotype/phenotype relationships. Human Genomics. 2014 May 22;8(1):9. DOI: 10.1186/1479-7364-8-9Search in Google Scholar
Hélias-Rodzewicz Z, Funck-Brentano E, Baudoux L, Jung CK, Zimmermann U, Marin C, et al. Variations of BRAF mutant allele percentage in melanomas. BMC Cancer. 2015 Jul 4;15:497. DOI: 10.1186/s12885-015-1515-3Search in Google Scholar
Dong J, Phelps RG, Qiao R, Yao S, Benard O, Ronai Z, et al. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res. 2003 Jul 15;63(14):3883-5.Search in Google Scholar
Orlova KV, Ledin EV, Zhukova NV, Orlova RV, Karabina EV, Volkonskiy MV, et al. Real-world experience with targeted therapy in BRAF mutant advanced melanoma patients: results from a multicenter retrospective observational study advanced melanoma in russia(Experience)(Admire). Cancers (Basel). 2021 May 21;13(11):2529. DOI: 10.3390/cancers13112529Search in Google Scholar
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002 Jun 27;417(6892):949-54.Search in Google Scholar
Genomic classification of cutaneous melanoma. Cell. 2015 Jun 18;161(7):1681-96.Search in Google Scholar
Gray PN, Dunlop CLM, Elliott AM. Not all next generation sequencing diagnostics are created equal: understanding the nuances of solid tumor assay design for somatic mutation detection. Cancers (Basel). 2015 Jul 17;7(3):1313-32. DOI: 10.3390/cancers7030837Search in Google Scholar
Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer. 2009 Aug 18;101(4):715-21. DOI: 10.1038/sj.bjc.6605177Search in Google Scholar
Whyte DB, Kirschmeier P, Hockenberry TN, Nunez-Oliva I, James L, Catino JJ, et al. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem. 1997 May 30;272(22):14459-64. DOI: 10.1074/jbc.272.22.14459Search in Google Scholar
Brock EJ, Ji K, Reiners JJ, Mattingly RR. How to target activated ras proteins: direct inhibition vs. Induced mislocalization. Mini Rev Med Chem. 2016;16(5):358-69. DOI: 10.2174/13895575156661 51001154002Search in Google Scholar
Dienstmann R, Dong F, Borger D, Dias-Santagata D, Ellisen LW, Le LP, et al. Standardized decision support in next generation sequencing reports of somatic cancer variants. Mol Oncol. 2014 Jul;8(5):859-73. DOI: 10.1016/j.molonc.2014.03.021Search in Google Scholar
Holleman MS, van Tinteren H, Groen HJ, Al MJ, Uyl-de Groot CA. First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis. Onco Targets Ther. 2019;12:1413-21. DOI: 10.2147/OTT.S189438Search in Google Scholar
Schulze AB, Evers G, Kerkhoff A, Mohr M, Schliemann C, Berdel WE, et al. Future options of molecular-targeted therapy in small cell lung cancer. Cancers (Basel). 2019 May 17;11(5):690. DOI: 10.3390/cancers11050690Search in Google Scholar
Yuan M, Huang LL, Chen JH, Wu J, Xu Q. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Target Ther. 2019 Dec 17;4:61. DOI: 10.1038/s41392-019-0099-9Search in Google Scholar
Martins M, Mansinho A, Cruz-Duarte R, Martins SL, Costa L. Anti-EGFR therapy to treat metastatic colorectal cancer: not for all. In: Jordan P, editor. Targeted Therapy of Colorectal Cancer Subtypes [Internet]. Cham: Springer International Publishing; 2018. p. 113-31. DOI: 10.1007/978-3-030-02771-1_8Search in Google Scholar
Spagnuolo A, Maione P, Gridelli C. Evolution in the treatment landscape of non-small cell lung cancer with ALK gene alterations: from the first- to third-generation of ALK inhibitors. Expert Opinion on Emerging Drugs. 2018 Jul 3;23(3):231-41. DOI: 10.1080/14728214.2018.1527902Search in Google Scholar
Meric-Bernstam F, Johnson AM, Dumbrava EEI, Raghav K, Balaji K, Bhatt M, et al. Advances in her2-targeted therapy: novel agents and opportunities beyond breast and gastric cancer. Clinical Cancer Research. 2019 Apr 1;25(7):2033-41. DOI: 10.1158/1078-0432.CCR-18-2275Search in Google Scholar
Song LJ, Ge HJ, Shi XQ, Shen WW. Prognostic and predictive values of the KIT11-mutated grading system in patients with gastrointestinal stromal tumors: a retrospective study. Human Pathology. 2021 Apr;110:31-42. DOI: 10.1016/j. humpath.2021.01.001Search in Google Scholar
Shen Y, Ma X, Wang M, Zhuang C, Ni B, Tu L, et al. Exon 11 homozygous mutations and intron 10/exon 11 junction deletions in the KIT gene are associated with poor prognosis of patients with gastrointestinal stromal tumors. Cancer Med. 2020 Jul 22;9(18):6485-96. DOI: 10.1002/cam4.3212Search in Google Scholar
Martín-Algarra S, Fernández-Figueras MT, López-Martín JA, Santos-Briz A, Arance A, Lozano MD, et al. Guidelines for biomarker testing in metastatic melanoma: a national consensus of the spanish society of pathology and the spanish society of medical oncology. Clin Transl Oncol. 2014 Apr;16(4):362-73. DOI: 10.1007/s12094-013-1090-5Search in Google Scholar
Liu X, Wu C, Li C, Boerwinkle E. Dbnsfp v3. 0: a one-stop database of functional predictions and annotations for human nonsynonymous and splice-site snvs. Hum Mutat. 2016 Mar;37(3):235-41. DOI: 10.1002/humu.22932Search in Google Scholar
Liu X, Li C, Mou C, Dong Y, Tu Y. Dbnsfp v4: a comprehensive database of transcript-specific functional predictions and annotations for human nonsynonymous and splice-site snvs. Genome Medicine. 2020 Dec 2;12(1):103. DOI: 10.1186/s13073-020-00803-9Search in Google Scholar
Madhavan S, Subramaniam S, Brown TD, Chen JL. Art and challenges of precision medicine: interpreting and integrating genomic data into clinical practice. Am Soc Clin Oncol Educ Book. 2018 May 23;38:546-53. DOI: 10.1200/EDBK_200759Search in Google Scholar
Westphalen CB, Krebs MG, Le Tourneau C, Sokol ES, Maund SL, Wilson TR, et al. Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population. npj Precis Onc. 2021 Jul 20;5(1):69. DOI: 10.1038/s41698-021-00206-ySearch in Google Scholar
Woodhouse R, Li M, Hughes J, Delfosse D, Skoletsky J, Ma P, et al. Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. Ha P, editor. PLoS ONE. 2020 Sep 25;15(9):e0237802. DOI: 10.1371/journal. pone.0237802Search in Google Scholar
Schettini F, De Santo I, Rea CG, De Placido P, Formisano L, Giuliano M, et al. CDK 4/6 inhibitors as single agent in advanced solid tumors. Front Oncol. 2018 Dec 12;8:608. DOI: 10.3389/fonc.2018.00608Search in Google Scholar
Spring LM, Wander SA, Zangardi M, Bardia A. CDK 4/6 inhibitors in breast cancer: current controversies and future directions. Curr Oncol Rep. 2019 Mar;21(3):25. DOI: 10.1007/s11912-019-0769-3Search in Google Scholar
Li CJ, Tzeng YDT, Chiu YH, Lin HY, Hou MF, Chu PY. Pathogenesis and potential therapeutic targets for triple-negative breast cancer. Cancers. 2021 Jun 14;13(12):2978. DOI: 10.3390/cancers13122978Search in Google Scholar
Bartlett JMS, Brookes CL, Robson T, van de Velde CJH, Billingham LJ, Campbell FM, et al. Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the tamoxifen and exemestane adjuvant multinational trial. JCO. 2011 Apr 20;29(12):1531-8. DOI: 10.1200/JCO.2010.30.3677Search in Google Scholar
Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. Non-small cell lung cancer, version 3. 2022, nccn clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022 May;20(5):497-530.Search in Google Scholar
Massard C, Michiels S, Ferté C, Le Deley MC, Lacroix L, Hollebecque A, et al. High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the moscato 01 trial. Cancer Discovery. 2017 Jun 1;7(6):586-95. DOI: 10.1158/2159-8290.CD-16-1396Search in Google Scholar
Rodon J, Soria JC, Berger R, Miller WH, Rubin E, Kugel A, et al. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat Med. 2019 May;25(5):751-8. DOI: 10.1038/s41591-019-0424-4Search in Google Scholar
Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010 Oct 28;363(18):1693-703. DOI: 10.1056/NEJMoa1006448Search in Google Scholar
Non-small cell lung carcinoma - my cancer genome [Internet]. [cited 2021 Oct 22]. Available from: https://www.mycancergenome.org/content/disease/non-small-cell-lung-carcinoma/Search in Google Scholar
Heemskerk-Gerritsen BAM, Rookus MA, Aalfs CM, Ausems MGEM, Collée JM, Jansen L, et al. Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis. Int J Cancer. 2015 Feb 1;136(3):668-77. DOI: 10.1002/ijc.29032Search in Google Scholar
Collins LC, Cole KS, Marotti JD, Hu R, Schnitt SJ, Tamimi RM. Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses’ Health Study. Modern Pathology. 2011 Jul;24(7):924-31. DOI: 10.1038/modpathol.2011.54Search in Google Scholar
Hynes NE, Dey JH. Potential for targeting the fibroblast growth factor receptors in breast cancer. Cancer Research. 2010 Jul 1;70(13):5199-202. DOI: 10.1158/0008-5472.CAN-10-0918Search in Google Scholar
Jain VK, Turner NC. Challenges and opportunities in the targeting of fibroblast growth factor receptors in breast cancer. Breast Cancer Res. 2012 Jun;14(3):208. DOI: 10.1186/bcr3139Search in Google Scholar
Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Research. 2010 Mar 1;70(5):2085-94. DOI: 10.1158/0008-5472. CAN-09-3746Search in Google Scholar
Heiskanen M, Kononen J, Bärlund M, Torhorst J, Sauter G, Kallioniemi A, et al. Cgh, cDNA and tissue microarray analyses implicate FGFR2 amplification in a small subset of breast tumors. Analytical Cellular Pathology. 2001;22(4):229-34. DOI: 10.1155/2001/981218Search in Google Scholar
Peixoto A, Pinto P, Guerra J, Pinheiro M, Santos C, Pinto C, et al. Tumor testing for somatic and germline BRCA1/BRCA2 variants in ovarian cancer patients in the context of strong founder effects. Front Oncol. 2020 Jul 31;10:1318. DOI: 10.3389/fonc.2020.01318Search in Google Scholar
The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011 Jun 30;474(7353):609-15. DOI: 10.1038/nature10166Search in Google Scholar
Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019 Dec 19;381(25):2416-28. DOI: 10.1056/NEJMoa1911361Search in Google Scholar
Peixoto A, Santos C, Pinto P, Pinheiro M, Rocha P, Pinto C, et al. The role of targeted BRCA1 / BRCA2 mutation analysis in hereditary breast/ovarian cancer families of Portuguese ancestry. Clin Genet. 2015 Jul;88(1):41-8. DOI: 10.1111/cge.12441Search in Google Scholar
The Cancer Genome Atlas Research Network, Levine DA. Integrated genomic characterization of endometrial carcinoma. Nature. 2013 May 2;497(7447):67-73. DOI: 10.1038/nature12113Search in Google Scholar
León-Castillo A, Britton H, McConechy MK, McAlpine JN, Nout R, Kommoss S, et al. Interpretation of somatic POLE mutations in endometrial carcinoma. J Pathol. 2020 Mar;250(3):323-35. DOI: 10.1002/path.5372Search in Google Scholar
Yao Z, Torres NM, Tao A, Gao Y, Luo L, Li Q, et al. BRAF mutants evade erk-dependent feedback by different mechanisms that determine their sensitivity to pharmacologic inhibition. Cancer Cell. 2015 Sep;28(3):370-83. DOI: 10.1016/j.ccell.2015.08.001Search in Google Scholar
Yao Z, Yaeger R, Rodrik-Outmezguine VS, Tao A, Torres NM, Chang MT, et al. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature. 2017 Aug;548(7666):234-8. DOI: 10.1038/nature23291Search in Google Scholar
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004 Jun 3;350(23):2335-42. DOI: 10.1056/NEJMoa032691Search in Google Scholar
Michielin O, van Akkooi ACJ, Ascierto PA, Dummer R, Keilholz U. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2019 Dec;30(12):1884-901. DOI: 10.1093/annonc/mdz411Search in Google Scholar
Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, et al. Colon cancer, version 2. 2021, nccn clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. 2021 Mar 2;19(3):329-59. DOI: 10.6004/jnccn.2021.0012Search in Google Scholar
Fumagalli D, Gavin PG, Taniyama Y, Kim SI, Choi HJ, Paik S, et al. A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes. BMC Cancer. 2010 Mar 16;10:101. DOI: 10.1186/1471-2407-10-101Search in Google Scholar
Tran NH, Cavalcante LL, Lubner SJ, Mulkerin DL, LoConte NK, Clipson L, et al. Precision medicine in colorectal cancer: the molecular profile alters treatment strategies. Ther Adv Med Oncol. 2015 Sep;7(5):252-62. DOI: 10.1177/1758834015591952Search in Google Scholar
Chen RZ, Pettersson U, Beard C, Jackson-Grusby L, Jaenisch R. DNA hypomethylation leads to elevated mutation rates. Nature. 1998 Sep;395(6697):89-93. DOI: 10.1038/25779Search in Google Scholar
Ogawa O, Eccles MR, Szeto J, McNoe LA, Yun K, Maw MA, et al. Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms’ tumour. Nature. 1993 Apr;362(6422):749-51. DOI: 10.1038/362749a0Search in Google Scholar
Midgley RS, McConkey CC, Johnstone EC, Dunn JA, Smith JL, Grumett SA, et al. Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the victor trial. JCO. 2010 Oct 20;28(30):4575-80. DOI: 10.1200/JCO.2010.29.6244Search in Google Scholar
Colorectal carcinoma - my cancer genome [Internet]. [cited 2021 Sept 21]. Available from: https://www.mycancergenome.org/content/disease/colorectal-carcinoma/Search in Google Scholar
Sepulveda AR, Hamilton SR, Allegra CJ, Grody W, Cushman-Vokoun AM, Funkhouser WK, et al. Molecular biomarkers for the evaluation of colorectal cancer: guideline from the american society for clinical pathology, college of american pathologists, association for molecular pathology, and the american society of clinical oncology. JCO. 2017 May 1;35(13):1453-86. DOI: 10.1200/JCO.2016.71.9807Search in Google Scholar
Beale S, Dickson R, Bagust A, Blundell M, Dundar Y, Boland A, et al. Vemurafenib for the treatment of locally advanced or metastatic BRAF v600 mutation-positive malignant melanoma: a nice single technology appraisal. PharmacoEconomics. 2013 Dec;31(12):1121-9. DOI: 10.1007/s40273-013-0094-xSearch in Google Scholar
Benson AB, D’Angelica MI, Abbott DE, Anaya DA, Anders R, Are C, et al. Hepatobiliary cancers, version 2. 2021, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. 2021 May 1;19(5):541-65. DOI: 10.6004/jnccn.2021.0022Search in Google Scholar
Krzyszczyk P, Acevedo A, Davidoff EJ, Timmins LM, Marrero-Berrios I, Patel M, et al. The growing role of precision and personalized medicine for cancer treatment. Technology. 2018 Sep;06(03n04):79-100. DOI: 10.1142/S2339547818300020Search in Google Scholar
Gambardella V, Tarazona N, Cejalvo JM, Lombardi P, Huerta M, Roselló S, et al. Personalized medicine: recent progress in cancer therapy. Cancers. 2020 Apr 19;12(4):1009. DOI: 10.3390/cancers12041009Search in Google Scholar
McGranahan N, Swanton C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell. 2015 Jan;27(1):15-26. DOI: 10.1016/j.ccell.2014.12.001Search in Google Scholar
Zhang L, Li Z, Skrzypczynska KM, Fang Q, Zhang W, O’Brien SA, et al. Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer. Cell. 2020 Apr;181(2):442-459.e29. DOI: 10.1016/j.cell.2020.03.048Search in Google Scholar
Le Tourneau C, Belin L, Paoletti X, Bièche I, Kamal M. Precision medicine: lessons learned from the SHIVA trial - Authors’ reply. Lancet Oncol. 2015 Dec;16(16):e581-582. DOI: 10.1016/S1470-2045(15)00455-6Search in Google Scholar
Le Tourneau C, Delord JP, Gonçalves A, Gavoille C, Dubot C, Isambert N, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015 Oct;16(13):1324-34. DOI: 10.1016/S1470-2045(15)00188-6Search in Google Scholar
Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018 Feb 22;378(8):731-9. DOI: 10.1056/NEJMoa1714448Search in Google Scholar
Märkl B, Hirschbühl K, Dhillon C. NTRK-Fusions - A new kid on the block. Pathology - Research and Practice. 2019 Oct;215(10):152572. DOI: 10.1016/j.prp.2019.152572Search in Google Scholar
Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018 Feb;15(2):95-111. DOI: 10.1038/nrclinonc.2017.157Search in Google Scholar
Kalyan A, Kircher S, Shah H, Mulcahy M, Benson A. Updates on immunotherapy for colorectal cancer. J Gastrointest Oncol. 2018 Feb;9(1):160-9. DOI: 10.21037/jgo.2018.01.17Search in Google Scholar
Larotrectinib Sulfate (Vitraki) prescribing information. Revised November 2018. Available at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210861Search in Google Scholar
Erdafitinib (Balversa) prescribing information. Revised April 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdfSearch in Google Scholar
Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR -mutated advanced non-small-cell lung cancer. N Engl J Med. 2018 Jan 11;378(2):113-25. DOI: 10.1056/NEJMoa1713137Search in Google Scholar
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PDL1-positive non-small-cell lung cancer. N Engl J Med. 2016 Nov 10;375(19):1823-33. DOI: 10.1056/NEJMoa1606774Search in Google Scholar
Pilié PG, Gay CM, Byers LA, O’Connor MJ, Yap TA. PARP inhibitors: extending benefit beyond BRCA -mutant cancers. Clinical Cancer Research. 2019 Jul 1;25(13):3759-71. DOI: 10.1158/1078-0432. CCR-18-0968Search in Google Scholar
Lavin Y, Kobayashi S, Leader A, Amir EAD, Elefant N, Bigenwald C, et al. Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses. Cell. 2017 May 4;169(4):750-765.e17. DOI: 10.1016/j.cell.2017.04.014Search in Google Scholar
Farmer H, McCabe N, Lord CJ, Tutt ANJ, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005 Apr;434(7035):917-21. DOI: 10.1038/nature03445Search in Google Scholar
Melanoma - my cancer genome [Internet]. [cited 2021 July 22]. Available from: https://www.mycancergenome.org/content/disease/melanoma/Search in Google Scholar
Yofe I, Dahan R, Amit I. Single-cell genomic approaches for developing the next generation of immunotherapies. Nat Med. 2020 Feb;26(2):171-7. DOI: 10.1038/s41591-019-0736-4Search in Google Scholar
